Imprimis Pharmaceuticals Inc. (IMMY)

2.80
NASDAQ : Health Technology
Prev Close 2.80
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.35 / 3.39
Avg Volume 152.00K
Exchange NASDAQ
Shares Outstanding 21.05M
Market Cap 59.57M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Imprimis Pharmaceuticals To Present At The Canaccord Genuity 38th Annual Growth Conference On August 9, 2018

Imprimis Pharmaceuticals To Present At The Canaccord Genuity 38th Annual Growth Conference On August 9, 2018

SAN DIEGO, July 18, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that its Chief Executive Officer, Mark L.

ImprimisRx's Dropless® Steroid And Antibiotic Intravitreal Injection Featured In The Prestigious Journal Of Cataract And Refractive Surgery

Study finds Dropless® might be a safe option for glaucomatous eyes having cataract surgery with trabecular microbypass stent insertion

Surface Pharmaceuticals, Inc. Announces $20 Million Series A Financing From Flying L Partners

Investment will enable Surface to fund its development programs focused on FDA approval of its ocular disease drug candidates

Imprimis Pharmaceuticals Issued Composition Patent For Non-Opioid Conscious Sedation Formulation

Imprimis Pharmaceuticals Issued Composition Patent For Non-Opioid Conscious Sedation Formulation

Non-opioid IV-free procedural sedation and pain relief could aid in the battle against opioid abuse

EpiPen Price Relief Could Come From Rivals Before Politicians

EpiPen Price Relief Could Come From Rivals Before Politicians

Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.

These 5 Under-$10 Stocks Are Set to Soar Higher

These 5 Under-$10 Stocks Are Set to Soar Higher

These under-$10 stocks look poised to break out and trade higher from current levels.

These 7 Stocks Under $10 Are Set to Soar Higher

These 7 Stocks Under $10 Are Set to Soar Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

3 Stocks Pushing The Drugs Industry Lower

3 Stocks Pushing The Drugs Industry Lower

TheStreet highlights 3 stocks pushing the Drugs industry lower today.

Biotech Sector Performance February 2014: Red Hot But...

Biotech Sector Performance February 2014: Red Hot But...

An epic month of biotech stock performance ends with a significant sell off.

Imprimis Pharmaceuticals Innovates Back to Basics With Compounding

Imprimis Pharmaceuticals Innovates Back to Basics With Compounding

Few firms are positioned to take advantage of a custom Rx trend, but Imprimis has a helpful partner.

Faruqi & Faruqi, LLP Launches An Investigation Against Imprimis Pharmaceuticals, Inc. (IMMY) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors

Faruqi & Faruqi, LLP Launches An Investigation Against Imprimis Pharmaceuticals, Inc. (IMMY) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Imprimis Pharmaceuticals, Inc.

Reset Needed

A good shakeup makes for more interesting trading.

Ratings Changes To Be Publicly Issued on 5/31/13

Upgrades: ALJ, APWC, EXH, GTN.A, HCOM, LIWA, MOBI, OSTK, SWFT, TMS, VOC Downgrades: ACU, ADK, AXR, BRP, BXE, CAP, CITZ, CLMS, CRWN, CTIB, CVTI, DAVE, DYNT, EDGW, EMMS, ESTE, HTCO, IRIX, LMIA, LNBB, MASC, MCBI, MHH, MOC, NBBC, NOVB, NWPX, PMBC, PNRG, PZZI, RBCAA, RCKY, STRN, SYNL, TOWR, TWIN, UBCP, UMPQ, USAP, WLFC Initiations: AQ, IMMY Read on to get TheStreet Quant Ratings' detailed report:

2 Biotech Stocks Under $10 to Watch

2 Biotech Stocks Under $10 to Watch

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

TheStreet Quant Rating: D- (Sell)